Tricida Investor Relations Material
Latest events
Q2 2022
Tricida
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Tricida Inc
Access all reports
Tricida Inc. is a pharmaceutical company focused on developing therapies for chronic kidney disease (CKD). The company’s lead investigational drug is designed to treat metabolic acidosis, a common complication in patients with CKD, which can lead to disease progression. Tricida aims to address unmet medical needs in the nephrology space by developing therapies that improve kidney health and patient outcomes. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
TCDA
Country
🇺🇸 United States